BUB1B_HUMAN
ID BUB1B_HUMAN Reviewed; 1050 AA.
AC O60566; B2R6U0; B4DL09; B4DLG3; O60501; O60627; O60758; O75389; Q59HH6;
AC Q8WV50; Q96KM4;
DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT 03-APR-2007, sequence version 3.
DT 03-AUG-2022, entry version 215.
DE RecName: Full=Mitotic checkpoint serine/threonine-protein kinase BUB1 beta;
DE EC=2.7.11.1;
DE AltName: Full=MAD3/BUB1-related protein kinase;
DE Short=hBUBR1;
DE AltName: Full=Mitotic checkpoint kinase MAD3L;
DE AltName: Full=Protein SSK1;
GN Name=BUB1B; Synonyms=BUBR1, MAD3L, SSK1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RC TISSUE=Umbilical vein;
RX PubMed=9618306; DOI=10.1006/bbrc.1998.8713;
RA Donadelli R., Benatti L., Remuzzi A., Morigi M., Gullans S.R., Benigni A.,
RA Remuzzi G., Noris M.;
RT "Identification of a novel gene -- SSK1 -- in human endothelial cells
RT exposed to shear stress.";
RL Biochem. Biophys. Res. Commun. 246:881-887(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RX PubMed=9660858; DOI=10.1083/jcb.142.1.1;
RA Taylor S.S., Ha E., McKeon F.;
RT "The human homologue of Bub3 is required for kinetochore localization of
RT Bub1 and a Mad3/Bub1-related protein kinase.";
RL J. Cell Biol. 142:1-11(1998).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH CENPE, SUBCELLULAR
RP LOCATION, AND VARIANT GLN-349.
RX PubMed=9763420; DOI=10.1083/jcb.143.1.49;
RA Chan G.K.T., Schaar B.T., Yen T.J.;
RT "Characterization of the kinetochore binding domain of CENP-E reveals
RT interactions with the kinetochore proteins CENP-F and hBUBR1.";
RL J. Cell Biol. 143:49-63(1998).
RN [4]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-15 AND GLN-349.
RX PubMed=9521327; DOI=10.1038/32688;
RA Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V.,
RA Markowitz S.D., Kinzler K.W., Vogelstein B.;
RT "Mutations of mitotic checkpoint genes in human cancers.";
RL Nature 392:300-303(1998).
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=9889005; DOI=10.1006/geno.1998.5629;
RA Davenport J.W., Fernandes E.R., Harris L.D., Neale G.A.M., Goorha R.;
RT "The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is
RT expressed in a cell cycle-dependent manner.";
RL Genomics 55:113-117(1999).
RN [6]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-349.
RA Dai W., Ouyang B., Lan Z., Pan H.;
RT "Human MAD3-like protein kinase (hmad3).";
RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN [7]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA Seike M., Gemma A., Hosoya Y., Kurimoto F., Yoshimura A., Kudoh S.;
RL Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN [8]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP GLN-349.
RC TISSUE=Tongue;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [9]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Brain;
RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA Ohara O., Nagase T., Kikuno R.F.;
RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN [10]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS GLN-349
RP AND SER-378.
RC TISSUE=Placenta;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [11]
RP PHOSPHORYLATION, TISSUE SPECIFICITY, AND INDUCTION.
RX PubMed=10593653;
RA Li W., Lan Z., Wu H., Wu S., Meadows J., Chen J., Zhu V., Dai W.;
RT "BUBR1 phosphorylation is regulated during mitotic checkpoint activation.";
RL Cell Growth Differ. 10:769-775(1999).
RN [12]
RP FUNCTION, SUBCELLULAR LOCATION, INDUCTION, PHOSPHORYLATION, AND INTERACTION
RP WITH APC/C.
RX PubMed=10477750; DOI=10.1083/jcb.146.5.941;
RA Chan G.K., Jablonski S.A., Sudakin V., Hittle J.C., Yen T.J.;
RT "Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions
RT at kinetochores and binds the cyclosome/APC.";
RL J. Cell Biol. 146:941-954(1999).
RN [13]
RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH CDC20 AND BUB3, AND MUTAGENESIS
RP OF LYS-795.
RX PubMed=11702782; DOI=10.1016/s1534-5807(01)00019-3;
RA Tang Z., Bharadwaj R., Li B., Yu H.;
RT "Mad2-independent inhibition of APC/Cdc20 by the mitotic checkpoint protein
RT BubR1.";
RL Dev. Cell 1:227-237(2001).
RN [14]
RP FUNCTION, SUBCELLULAR LOCATION, AND DEGRADATION BY THE PROTEASOME.
RX PubMed=14706340; DOI=10.1016/s1535-6108(03)00302-7;
RA Shin H.J., Baek K.H., Jeon A.H., Park M.T., Lee S.J., Kang C.M., Lee H.S.,
RA Yoo S.H., Chung D.H., Sung Y.C., McKeon F., Lee C.W.;
RT "Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring
RT of chromosomal instability.";
RL Cancer Cell 4:483-497(2003).
RN [15]
RP ACTIVITY REGULATION, INTERACTION WITH CENPE, AUTOPHOSPHORYLATION, AND
RP MUTAGENESIS OF LYS-795.
RX PubMed=12925705; DOI=10.1083/jcb.200303167;
RA Weaver B.A., Bonday Z.Q., Putkey F.R., Kops G.J., Silk A.D.,
RA Cleveland D.W.;
RT "Centromere-associated protein-E is essential for the mammalian mitotic
RT checkpoint to prevent aneuploidy due to single chromosome loss.";
RL J. Cell Biol. 162:551-563(2003).
RN [16]
RP FUNCTION.
RX PubMed=15020684; DOI=10.1242/jcs.01006;
RA Johnson V.L., Scott M.I., Holt S.V., Hussein D., Taylor S.S.;
RT "Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and
RT Mad2, and chromosome congression.";
RL J. Cell Sci. 117:1577-1589(2004).
RN [17]
RP PROTEOLYTIC CLEAVAGE AT ASP-579 AND ASP-610 BY CASPASE-3, INDUCTION, AND
RP MUTAGENESIS OF ASP-579 AND ASP-610.
RX PubMed=16227576; DOI=10.1128/mcb.25.21.9232-9248.2005;
RA Kim M., Murphy K., Liu F., Parker S.E., Dowling M.L., Baff W., Kao G.D.;
RT "Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic
RT progression.";
RL Mol. Cell. Biol. 25:9232-9248(2005).
RN [18]
RP SUBCELLULAR LOCATION, AND INTERACTION WITH PLK1.
RX PubMed=16760428; DOI=10.1091/mbc.e06-03-0240;
RA Qi W., Tang Z., Yu H.;
RT "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT required for the kinetochore localization of Plk1.";
RL Mol. Biol. Cell 17:3705-3716(2006).
RN [19]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=16964243; DOI=10.1038/nbt1240;
RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT "A probability-based approach for high-throughput protein phosphorylation
RT analysis and site localization.";
RL Nat. Biotechnol. 24:1285-1292(2006).
RN [20]
RP INTERACTION WITH KNL1, AND MUTAGENESIS OF ALA-159 AND PHE-175.
RX PubMed=17981135; DOI=10.1016/j.devcel.2007.09.005;
RA Kiyomitsu T., Obuse C., Yanagida M.;
RT "Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic
RT checkpoint through direct interaction with Bub1 and BubR1.";
RL Dev. Cell 13:663-676(2007).
RN [21]
RP INTERACTION WITH PLK1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-676,
RP AND MUTAGENESIS OF THR-620.
RX PubMed=17785528; DOI=10.1101/gad.436007;
RA Elowe S., Huemmer S., Uldschmid A., Li X., Nigg E.A.;
RT "Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of
RT kinetochore microtubule interactions.";
RL Genes Dev. 21:2205-2219(2007).
RN [22]
RP INTERACTION WITH PLK1, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-792
RP AND THR-1008.
RX PubMed=17376779; DOI=10.1074/jbc.m611053200;
RA Matsumura S., Toyoshima F., Nishida E.;
RT "Polo-like kinase 1 facilitates chromosome alignment during prometaphase
RT through BubR1.";
RL J. Biol. Chem. 282:15217-15227(2007).
RN [23]
RP PHOSPHORYLATION AT SER-435; SER-543; SER-670 AND SER-1043.
RX PubMed=19015317; DOI=10.1083/jcb.200805163;
RA Huang H., Hittle J., Zappacosta F., Annan R.S., Hershko A., Yen T.J.;
RT "Phosphorylation sites in BubR1 that regulate kinetochore attachment,
RT tension, and mitotic exit.";
RL J. Cell Biol. 183:667-680(2008).
RN [24]
RP SUMOYLATION.
RX PubMed=18374647; DOI=10.1016/j.molcel.2008.01.013;
RA Zhang X.-D., Goeres J., Zhang H., Yen T.J., Porter A.C.G., Matunis M.J.;
RT "SUMO-2/3 modification and binding regulate the association of CENP-E with
RT kinetochores and progression through mitosis.";
RL Mol. Cell 29:729-741(2008).
RN [25]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA Greff Z., Keri G., Stemmann O., Mann M.;
RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT kinome across the cell cycle.";
RL Mol. Cell 31:438-448(2008).
RN [26]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [27]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=19413330; DOI=10.1021/ac9004309;
RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT refined SCX-based approach.";
RL Anal. Chem. 81:4493-4501(2009).
RN [28]
RP FUNCTION.
RX PubMed=19411850; DOI=10.4161/cc.8.11.8671;
RA Park S.-Y., Kim S., Cho H., Kwon S.-H., Chae S., Kang D., Seong Y.-S.,
RA Cho H.;
RT "Depletion of BubR1 promotes premature centrosomal localization of cyclin
RT B1 and accelerates mitotic entry.";
RL Cell Cycle 8:1754-1764(2009).
RN [29]
RP INTERACTION WITH CENPE, AND SUBCELLULAR LOCATION.
RX PubMed=19625775; DOI=10.4161/cc.8.16.9366;
RA Huang Y., Yao Y., Xu H.-Z., Wang Z.-G., Lu L., Dai W.;
RT "Defects in chromosome congression and mitotic progression in KIF18A-
RT deficient cells are partly mediated through impaired functions of CENP-E.";
RL Cell Cycle 8:2643-2649(2009).
RN [30]
RP INTERACTION WITH KAT2B, ACETYLATION AT LYS-250, AND UBIQUITINATION.
RX PubMed=19407811; DOI=10.1038/emboj.2009.123;
RA Choi E., Choe H., Min J., Choi J.Y., Kim J., Lee H.;
RT "BubR1 acetylation at prometaphase is required for modulating APC/C
RT activity and timing of mitosis.";
RL EMBO J. 28:2077-2089(2009).
RN [31]
RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PLK1.
RX PubMed=19503101; DOI=10.1038/onc.2009.141;
RA Izumi H., Matsumoto Y., Ikeuchi T., Saya H., Kajii T., Matsuura S.;
RT "BubR1 localizes to centrosomes and suppresses centrosome amplification via
RT regulating Plk1 activity in interphase cells.";
RL Oncogene 28:2806-2820(2009).
RN [32]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-670 AND THR-1042, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT site occupancy during mitosis.";
RL Sci. Signal. 3:RA3-RA3(2010).
RN [33]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA Bennett K.L., Superti-Furga G., Colinge J.;
RT "Initial characterization of the human central proteome.";
RL BMC Syst. Biol. 5:17-17(2011).
RN [34]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT "System-wide temporal characterization of the proteome and phosphoproteome
RT of human embryonic stem cell differentiation.";
RL Sci. Signal. 4:RS3-RS3(2011).
RN [35]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-435; SER-543;
RP SER-665; SER-670 AND SER-697, AND IDENTIFICATION BY MASS SPECTROMETRY
RP [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma, and Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [36]
RP INTERACTION WITH MAD2L1.
RX PubMed=29162720; DOI=10.1074/jbc.ra117.000555;
RA Ji W., Luo Y., Ahmad E., Liu S.T.;
RT "Direct interactions of mitotic arrest deficient 1 (MAD1) domains with each
RT other and MAD2 conformers are required for mitotic checkpoint signaling.";
RL J. Biol. Chem. 293:484-496(2018).
RN [37]
RP INTERACTION WITH RIPK3.
RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016;
RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K.,
RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.;
RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent
RT proteasomal degradation.";
RL Mol. Cell 70:920-935(2018).
RN [38]
RP VARIANTS GLN-349 AND ALA-618.
RX PubMed=10366450; DOI=10.1006/geno.1999.5831;
RA Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W.,
RA Vogelstein B., Lengauer C.;
RT "Characterization of MAD2B and other mitotic spindle checkpoint genes.";
RL Genomics 58:181-187(1999).
RN [39]
RP VARIANTS MVA1 GLN-550; HIS-814; PHE-844; THR-909; HIS-921 AND PRO-1012.
RX PubMed=15475955; DOI=10.1038/ng1449;
RA Hanks S., Coleman K., Reid S., Plaja A., Firth H., Fitzpatrick D., Kidd A.,
RA Mehes K., Nash R., Robin N., Shannon N., Tolmie J., Swansbury J.,
RA Irrthum A., Douglas J., Rahman N.;
RT "Constitutional aneuploidy and cancer predisposition caused by biallelic
RT mutations in BUB1B.";
RL Nat. Genet. 36:1159-1161(2004).
RN [40]
RP VARIANT PCS GLN-36.
RX PubMed=16411201; DOI=10.1002/ajmg.a.31069;
RA Matsuura S., Matsumoto Y., Morishima K., Izumi H., Matsumoto H., Ito E.,
RA Tsutsui K., Kobayashi J., Tauchi H., Kajiwara Y., Hama S., Kurisu K.,
RA Tahara H., Oshimura M., Komatsu K., Ikeuchi T., Kajii T.;
RT "Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in
RT seven families with premature chromatid separation (PCS) syndrome.";
RL Am. J. Med. Genet. A 140:358-367(2006).
RN [41]
RP VARIANTS [LARGE SCALE ANALYSIS] MET-40; GLN-349; ASP-390 AND ALA-618.
RX PubMed=17344846; DOI=10.1038/nature05610;
RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA Futreal P.A., Stratton M.R.;
RT "Patterns of somatic mutation in human cancer genomes.";
RL Nature 446:153-158(2007).
CC -!- FUNCTION: Essential component of the mitotic checkpoint. Required for
CC normal mitosis progression. The mitotic checkpoint delays anaphase
CC until all chromosomes are properly attached to the mitotic spindle. One
CC of its checkpoint functions is to inhibit the activity of the anaphase-
CC promoting complex/cyclosome (APC/C) by blocking the binding of CDC20 to
CC APC/C, independently of its kinase activity. The other is to monitor
CC kinetochore activities that depend on the kinetochore motor CENPE.
CC Required for kinetochore localization of CENPE. Negatively regulates
CC PLK1 activity in interphase cells and suppresses centrosome
CC amplification. Also implicated in triggering apoptosis in polyploid
CC cells that exit aberrantly from mitotic arrest. May play a role for
CC tumor suppression. {ECO:0000269|PubMed:10477750,
CC ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:14706340,
CC ECO:0000269|PubMed:15020684, ECO:0000269|PubMed:19411850,
CC ECO:0000269|PubMed:19503101}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC EC=2.7.11.1;
CC -!- ACTIVITY REGULATION: Kinase activity stimulated by CENPE.
CC {ECO:0000269|PubMed:12925705}.
CC -!- SUBUNIT: Interacts with CENPE (PubMed:12925705, PubMed:19625775).
CC Interacts with PLK1 (PubMed:16760428, PubMed:17785528, PubMed:17376779,
CC PubMed:19503101). Part of a complex containing BUB3, CDC20 and BUB1B
CC (PubMed:11702782). Interacts with anaphase-promoting complex/cyclosome
CC (APC/C) (PubMed:10477750). Interacts with KNL1 (PubMed:17981135).
CC Interacts with KAT2B (PubMed:19407811). Interacts with RIPK3
CC (PubMed:29883609). Interacts with the closed conformation form of
CC MAD2L1 (PubMed:29162720). {ECO:0000269|PubMed:10477750,
CC ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:12925705,
CC ECO:0000269|PubMed:16760428, ECO:0000269|PubMed:17376779,
CC ECO:0000269|PubMed:17785528, ECO:0000269|PubMed:17981135,
CC ECO:0000269|PubMed:19407811, ECO:0000269|PubMed:19503101,
CC ECO:0000269|PubMed:19625775, ECO:0000269|PubMed:29162720,
CC ECO:0000269|PubMed:29883609}.
CC -!- INTERACTION:
CC O60566; O43683: BUB1; NbExp=3; IntAct=EBI-1001438, EBI-748936;
CC O60566; O43684: BUB3; NbExp=10; IntAct=EBI-1001438, EBI-1050987;
CC O60566; Q12834: CDC20; NbExp=33; IntAct=EBI-1001438, EBI-367462;
CC O60566; Q02224: CENPE; NbExp=4; IntAct=EBI-1001438, EBI-1375040;
CC O60566; Q92831: KAT2B; NbExp=14; IntAct=EBI-1001438, EBI-477430;
CC O60566; Q8NG31-2: KNL1; NbExp=10; IntAct=EBI-1001438, EBI-10973816;
CC O60566; Q13257: MAD2L1; NbExp=14; IntAct=EBI-1001438, EBI-78203;
CC O60566; Q8IXJ6: SIRT2; NbExp=3; IntAct=EBI-1001438, EBI-477232;
CC O60566; P0CG48: UBC; NbExp=3; IntAct=EBI-1001438, EBI-3390054;
CC O60566; P45481: Crebbp; Xeno; NbExp=3; IntAct=EBI-1001438, EBI-296306;
CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Chromosome, centromere,
CC kinetochore. Cytoplasm, cytoskeleton, microtubule organizing center,
CC centrosome. Note=Cytoplasmic in interphase cells. Associates with the
CC kinetochores in early prophase. Kinetochore localization requires BUB1,
CC PLK1 and KNL1.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=O60566-1; Sequence=Displayed;
CC Name=2;
CC IsoId=O60566-2; Sequence=VSP_036474, VSP_036475, VSP_036476;
CC Name=3;
CC IsoId=O60566-3; Sequence=VSP_036473;
CC -!- TISSUE SPECIFICITY: Highly expressed in thymus followed by spleen.
CC Preferentially expressed in tissues with a high mitotic index.
CC {ECO:0000269|PubMed:10593653}.
CC -!- INDUCTION: Induced during mitosis. {ECO:0000269|PubMed:10477750,
CC ECO:0000269|PubMed:10593653, ECO:0000269|PubMed:16227576}.
CC -!- DOMAIN: The D-box targets the protein for rapid degradation by
CC ubiquitin-dependent proteolysis during the transition from mitosis to
CC interphase. {ECO:0000305}.
CC -!- DOMAIN: The BUB1 N-terminal domain directs kinetochore localization and
CC binding to BUB3.
CC -!- PTM: Proteolytically cleaved by caspase-3 in a cell cycle specific
CC manner. The cleavage might be involved in the durability of the cell
CC cycle delay. Caspase-3 cleavage is associated with abrogation of the
CC mitotic checkpoint. The major site of cleavage is at Asp-610.
CC {ECO:0000269|PubMed:16227576}.
CC -!- PTM: Acetylation at Lys-250 regulates its degradation and timing in
CC anaphase entry. {ECO:0000269|PubMed:19407811}.
CC -!- PTM: Ubiquitinated. Degraded by the proteasome.
CC {ECO:0000269|PubMed:19407811}.
CC -!- PTM: Sumoylated with SUMO2 and SUMO3. The sumoylation mediates the
CC association with CENPE at the kinetochore.
CC {ECO:0000269|PubMed:18374647}.
CC -!- PTM: Autophosphorylated in vitro. Intramolecular autophosphorylation is
CC stimulated by CENPE. Phosphorylated during mitosis and
CC hyperphosphorylated in mitotically arrested cells. Phosphorylation at
CC Ser-670 and Ser-1043 occurs at kinetochores upon mitotic entry with
CC dephosphorylation at the onset of anaphase.
CC {ECO:0000269|PubMed:10477750, ECO:0000269|PubMed:10593653,
CC ECO:0000269|PubMed:17376779, ECO:0000269|PubMed:17785528,
CC ECO:0000269|PubMed:19015317}.
CC -!- DISEASE: Note=Defects in BUB1B are associated with tumor formation.
CC -!- DISEASE: Premature chromatid separation trait (PCS) [MIM:176430]:
CC Consists of separate and splayed chromatids with discernible
CC centromeres and involves all or most chromosomes of a metaphase. It is
CC found in up to 2% of metaphases in cultured lymphocytes from
CC approximately 40% of normal individuals. When PCS is present in 5% or
CC more of cells, it is known as the heterozygous PCS trait and has no
CC obvious phenotypic effect, although some have reported decreased
CC fertility. Inheritance is autosomal dominant.
CC {ECO:0000269|PubMed:16411201}. Note=The disease is caused by variants
CC affecting the gene represented in this entry.
CC -!- DISEASE: Mosaic variegated aneuploidy syndrome 1 (MVA1) [MIM:257300]: A
CC severe developmental disorder characterized by mosaic aneuploidies,
CC predominantly trisomies and monosomies, involving multiple different
CC chromosomes and tissues. Affected individuals typically present with
CC severe intrauterine growth retardation and microcephaly. Eye anomalies,
CC mild dysmorphism, variable developmental delay, and a broad spectrum of
CC additional congenital abnormalities and medical conditions may also
CC occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms
CC tumor and leukemia reported in several cases.
CC {ECO:0000269|PubMed:15475955}. Note=The disease is caused by variants
CC affecting the gene represented in this entry. MVA1 is caused by
CC biallelic mutations in the BUB1B gene.
CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC kinase family. BUB1 subfamily. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=BAD92019.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC Haematology;
CC URL="http://atlasgeneticsoncology.org/Genes/BUB1BID854ch15q15.html";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF053306; AAC06260.1; -; mRNA.
DR EMBL; AF046918; AAC33435.1; -; mRNA.
DR EMBL; AF046079; AAC12730.2; -; mRNA.
DR EMBL; AF107297; AAD11941.1; -; mRNA.
DR EMBL; AF035933; AAC23736.1; -; mRNA.
DR EMBL; AF068760; AAC19118.1; -; mRNA.
DR EMBL; AF310214; AAL10712.1; -; Genomic_DNA.
DR EMBL; AF310192; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310193; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310194; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310195; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310196; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310197; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310198; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310199; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310200; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310201; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310202; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310203; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310204; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310205; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310206; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310207; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310208; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310209; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310210; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310211; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310212; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AF310213; AAL10712.1; JOINED; Genomic_DNA.
DR EMBL; AK296795; BAG59371.1; -; mRNA.
DR EMBL; AK296984; BAG59525.1; -; mRNA.
DR EMBL; AK312709; BAG35587.1; -; mRNA.
DR EMBL; AB208782; BAD92019.1; ALT_INIT; mRNA.
DR EMBL; BC018739; AAH18739.1; -; mRNA.
DR CCDS; CCDS10053.1; -. [O60566-1]
DR PIR; JW0092; JW0092.
DR RefSeq; NP_001202.4; NM_001211.5. [O60566-1]
DR PDB; 2WVI; X-ray; 1.80 A; A=57-220.
DR PDB; 3SI5; X-ray; 2.20 A; A/B=57-220.
DR PDB; 4GGD; X-ray; 2.44 A; C/D=20-42.
DR PDB; 5JJA; X-ray; 2.35 A; C/D=647-720.
DR PDB; 5K6S; X-ray; 2.79 A; B=663-681.
DR PDB; 5KHU; EM; 4.80 A; Q=1-1050.
DR PDB; 5LCW; EM; 4.00 A; S=1-560.
DR PDB; 5SWF; X-ray; 2.82 A; B=668-676.
DR PDB; 6TLJ; EM; 3.80 A; S=1-1050.
DR PDBsum; 2WVI; -.
DR PDBsum; 3SI5; -.
DR PDBsum; 4GGD; -.
DR PDBsum; 5JJA; -.
DR PDBsum; 5K6S; -.
DR PDBsum; 5KHU; -.
DR PDBsum; 5LCW; -.
DR PDBsum; 5SWF; -.
DR PDBsum; 6TLJ; -.
DR AlphaFoldDB; O60566; -.
DR BMRB; O60566; -.
DR SMR; O60566; -.
DR BioGRID; 107166; 160.
DR ComplexPortal; CPX-3946; Mitotic Checkpoint Complex.
DR CORUM; O60566; -.
DR DIP; DIP-24203N; -.
DR ELM; O60566; -.
DR IntAct; O60566; 94.
DR MINT; O60566; -.
DR STRING; 9606.ENSP00000287598; -.
DR ChEMBL; CHEMBL4295998; -.
DR GlyConnect; 1516; 11 N-Linked glycans (1 site).
DR GlyGen; O60566; 2 sites, 11 N-linked glycans (1 site), 1 O-linked glycan (1 site).
DR iPTMnet; O60566; -.
DR MetOSite; O60566; -.
DR PhosphoSitePlus; O60566; -.
DR BioMuta; BUB1B; -.
DR EPD; O60566; -.
DR jPOST; O60566; -.
DR MassIVE; O60566; -.
DR MaxQB; O60566; -.
DR PaxDb; O60566; -.
DR PeptideAtlas; O60566; -.
DR PRIDE; O60566; -.
DR ProteomicsDB; 49471; -. [O60566-1]
DR ProteomicsDB; 49472; -. [O60566-2]
DR ProteomicsDB; 49473; -. [O60566-3]
DR ABCD; O60566; 1 sequenced antibody.
DR Antibodypedia; 1214; 746 antibodies from 41 providers.
DR DNASU; 701; -.
DR Ensembl; ENST00000287598.11; ENSP00000287598.7; ENSG00000156970.13. [O60566-1]
DR Ensembl; ENST00000412359.7; ENSP00000398470.3; ENSG00000156970.13. [O60566-3]
DR GeneID; 701; -.
DR KEGG; hsa:701; -.
DR MANE-Select; ENST00000287598.11; ENSP00000287598.7; NM_001211.6; NP_001202.5.
DR UCSC; uc001zkx.5; human. [O60566-1]
DR CTD; 701; -.
DR DisGeNET; 701; -.
DR GeneCards; BUB1B; -.
DR HGNC; HGNC:1149; BUB1B.
DR HPA; ENSG00000156970; Group enriched (bone marrow, lymphoid tissue, testis).
DR MalaCards; BUB1B; -.
DR MIM; 176430; phenotype.
DR MIM; 257300; phenotype.
DR MIM; 602860; gene.
DR neXtProt; NX_O60566; -.
DR OpenTargets; ENSG00000156970; -.
DR Orphanet; 1052; Mosaic variegated aneuploidy syndrome.
DR PharmGKB; PA82; -.
DR VEuPathDB; HostDB:ENSG00000156970; -.
DR eggNOG; KOG1166; Eukaryota.
DR GeneTree; ENSGT00940000158912; -.
DR HOGENOM; CLU_010890_0_0_1; -.
DR InParanoid; O60566; -.
DR OMA; CAKETSL; -.
DR OrthoDB; 1411806at2759; -.
DR PhylomeDB; O60566; -.
DR TreeFam; TF105456; -.
DR BRENDA; 2.7.11.1; 2681.
DR PathwayCommons; O60566; -.
DR Reactome; R-HSA-141430; Inactivation of APC/C via direct inhibition of the APC/C complex.
DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR Reactome; R-HSA-174184; Cdc20:Phospho-APC/C mediated degradation of Cyclin A.
DR Reactome; R-HSA-176409; APC/C:Cdc20 mediated degradation of mitotic proteins.
DR Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A.
DR Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR Reactome; R-HSA-68877; Mitotic Prometaphase.
DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR SignaLink; O60566; -.
DR SIGNOR; O60566; -.
DR BioGRID-ORCS; 701; 690 hits in 1119 CRISPR screens.
DR ChiTaRS; BUB1B; human.
DR EvolutionaryTrace; O60566; -.
DR GeneWiki; BUB1B; -.
DR GenomeRNAi; 701; -.
DR Pharos; O60566; Tbio.
DR PRO; PR:O60566; -.
DR Proteomes; UP000005640; Chromosome 15.
DR RNAct; O60566; protein.
DR Bgee; ENSG00000156970; Expressed in secondary oocyte and 133 other tissues.
DR ExpressionAtlas; O60566; baseline and differential.
DR Genevisible; O60566; HS.
DR GO; GO:0005680; C:anaphase-promoting complex; TAS:ProtInc.
DR GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR GO; GO:0005829; C:cytosol; IDA:HPA.
DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR GO; GO:0033597; C:mitotic checkpoint complex; IPI:ComplexPortal.
DR GO; GO:0000940; C:outer kinetochore; IDA:UniProtKB.
DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR GO; GO:0051754; P:meiotic sister chromatid cohesion, centromeric; IBA:GO_Central.
DR GO; GO:0007091; P:metaphase/anaphase transition of mitotic cell cycle; IEA:Ensembl.
DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IDA:UniProtKB.
DR GO; GO:0051444; P:negative regulation of ubiquitin-protein transferase activity; IDA:ComplexPortal.
DR GO; GO:0016310; P:phosphorylation; IEA:UniProtKB-KW.
DR GO; GO:0071459; P:protein localization to chromosome, centromeric region; IEA:Ensembl.
DR DisProt; DP01117; -.
DR IDEAL; IID00407; -.
DR InterPro; IPR015661; Bub1/Mad3.
DR InterPro; IPR011009; Kinase-like_dom_sf.
DR InterPro; IPR013212; Mad3/Bub1_I.
DR PANTHER; PTHR14030; PTHR14030; 1.
DR Pfam; PF08311; Mad3_BUB1_I; 1.
DR SMART; SM00777; Mad3_BUB1_I; 1.
DR SUPFAM; SSF56112; SSF56112; 1.
DR PROSITE; PS51489; BUB1_N; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW Cell cycle; Cell division; Centromere; Chromosome; Cytoplasm; Cytoskeleton;
KW Disease variant; Kinase; Kinetochore; Mitosis; Nucleotide-binding; Nucleus;
KW Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW Transferase; Tumor suppressor; Ubl conjugation.
FT CHAIN 1..1050
FT /note="Mitotic checkpoint serine/threonine-protein kinase
FT BUB1 beta"
FT /id="PRO_0000085673"
FT DOMAIN 62..226
FT /note="BUB1 N-terminal"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00822"
FT DOMAIN 766..1050
FT /note="Protein kinase"
FT REGION 152..185
FT /note="Necessary for interaction with KNL1"
FT /evidence="ECO:0000269|PubMed:17981135"
FT REGION 368..393
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 456..480
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOTIF 111..118
FT /note="Nuclear localization signal"
FT /evidence="ECO:0000255"
FT MOTIF 224..232
FT /note="D-box"
FT ACT_SITE 882
FT /note="Proton acceptor"
FT /evidence="ECO:0000250"
FT BINDING 772..780
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250"
FT BINDING 795
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250"
FT SITE 579..580
FT /note="Cleavage; by caspase-3"
FT /evidence="ECO:0000269|PubMed:16227576"
FT SITE 610..611
FT /note="Cleavage; by caspase-3"
FT /evidence="ECO:0000269|PubMed:16227576"
FT MOD_RES 250
FT /note="N6-acetyllysine; by PCAF"
FT /evidence="ECO:0000269|PubMed:19407811"
FT MOD_RES 367
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 435
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:19015317,
FT ECO:0007744|PubMed:23186163"
FT MOD_RES 543
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:19015317,
FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT MOD_RES 665
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 670
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:19015317,
FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT MOD_RES 676
FT /note="Phosphoserine; by PLK1"
FT /evidence="ECO:0000269|PubMed:17785528"
FT MOD_RES 697
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 792
FT /note="Phosphothreonine; by PLK1"
FT /evidence="ECO:0000269|PubMed:17376779"
FT MOD_RES 1008
FT /note="Phosphothreonine; by PLK1"
FT /evidence="ECO:0000269|PubMed:17376779"
FT MOD_RES 1042
FT /note="Phosphothreonine"
FT /evidence="ECO:0007744|PubMed:20068231"
FT MOD_RES 1043
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:19015317"
FT VAR_SEQ 80
FT /note="R -> RWVFLFHKDNRNINR (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_036473"
FT VAR_SEQ 113..166
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_036474"
FT VAR_SEQ 522
FT /note="K -> KVSLSL (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_036475"
FT VAR_SEQ 608..675
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_036476"
FT VARIANT 15
FT /note="M -> T (in a colorectal cancer cell line;
FT dbSNP:rs1392369693)"
FT /evidence="ECO:0000269|PubMed:9521327"
FT /id="VAR_008852"
FT VARIANT 36
FT /note="R -> Q (in PCS; dbSNP:rs534297115)"
FT /evidence="ECO:0000269|PubMed:16411201"
FT /id="VAR_028921"
FT VARIANT 40
FT /note="T -> M (in dbSNP:rs56079734)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_040402"
FT VARIANT 349
FT /note="R -> Q (in dbSNP:rs1801376)"
FT /evidence="ECO:0000269|PubMed:10366450,
FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9521327,
FT ECO:0000269|PubMed:9618306, ECO:0000269|PubMed:9660858,
FT ECO:0000269|PubMed:9763420, ECO:0000269|Ref.6"
FT /id="VAR_008853"
FT VARIANT 378
FT /note="P -> S (in dbSNP:rs17851677)"
FT /evidence="ECO:0000269|PubMed:15489334"
FT /id="VAR_054549"
FT VARIANT 390
FT /note="E -> D (in dbSNP:rs1017842)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_028922"
FT VARIANT 550
FT /note="R -> Q (in MVA1; heterozygous compound with nonsense
FT mutation; dbSNP:rs28989187)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028923"
FT VARIANT 618
FT /note="V -> A (in dbSNP:rs1801528)"
FT /evidence="ECO:0000269|PubMed:10366450,
FT ECO:0000269|PubMed:17344846"
FT /id="VAR_008854"
FT VARIANT 814
FT /note="R -> H (in MVA1; heterozygous compound with nonsense
FT mutation; dbSNP:rs28989182)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028924"
FT VARIANT 844
FT /note="L -> F (in MVA1; associated with H-921; heterozygous
FT compound with nonsense mutation; dbSNP:rs28989181)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028925"
FT VARIANT 909
FT /note="I -> T (in MVA1; heterozygous compound with nonsense
FT mutation; dbSNP:rs28989184)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028926"
FT VARIANT 921
FT /note="Q -> H (in MVA1; associated with F-844; heterozygous
FT compound with nonsense mutation; dbSNP:rs28989183)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028927"
FT VARIANT 1012
FT /note="L -> P (in MVA1; heterozygous compound with nonsense
FT mutation; dbSNP:rs28989185)"
FT /evidence="ECO:0000269|PubMed:15475955"
FT /id="VAR_028928"
FT MUTAGEN 159
FT /note="A->W: Loss of interaction with KNL1."
FT /evidence="ECO:0000269|PubMed:17981135"
FT MUTAGEN 175
FT /note="F->A: Loss of interaction with KNL1."
FT /evidence="ECO:0000269|PubMed:17981135"
FT MUTAGEN 579
FT /note="D->E: Abolishes the cleavage by caspase-3."
FT /evidence="ECO:0000269|PubMed:16227576"
FT MUTAGEN 610
FT /note="D->E: Abolishes the cleavage by caspase-3."
FT /evidence="ECO:0000269|PubMed:16227576"
FT MUTAGEN 620
FT /note="T->A: Induces chromosome congression defects and
FT mitotic delay."
FT /evidence="ECO:0000269|PubMed:17785528"
FT MUTAGEN 795
FT /note="K->A: Does not abolish the capacity to inhibit
FT APC/CDC20."
FT /evidence="ECO:0000269|PubMed:11702782,
FT ECO:0000269|PubMed:12925705"
FT MUTAGEN 795
FT /note="K->R: Inhibits kinase activity."
FT /evidence="ECO:0000269|PubMed:11702782,
FT ECO:0000269|PubMed:12925705"
FT CONFLICT 248..249
FT /note="AL -> VF (in Ref. 1; AAC23736)"
FT /evidence="ECO:0000305"
FT CONFLICT 283
FT /note="S -> P (in Ref. 8; BAG35587)"
FT /evidence="ECO:0000305"
FT CONFLICT 788
FT /note="S -> F (in Ref. 2; AAC06260)"
FT /evidence="ECO:0000305"
FT CONFLICT 1018
FT /note="E -> K (in Ref. 3; AAC33435)"
FT /evidence="ECO:0000305"
FT TURN 26..28
FT /evidence="ECO:0007829|PDB:4GGD"
FT HELIX 60..65
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 75..88
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 94..96
FT /evidence="ECO:0007829|PDB:3SI5"
FT HELIX 98..108
FT /evidence="ECO:0007829|PDB:2WVI"
FT TURN 109..111
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 113..115
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 119..131
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 135..144
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 152..164
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 168..180
FT /evidence="ECO:0007829|PDB:2WVI"
FT HELIX 186..218
FT /evidence="ECO:0007829|PDB:2WVI"
SQ SEQUENCE 1050 AA; 119545 MW; F7871103A56E6B46 CRC64;
MAAVKKEGGA LSEAMSLEGD EWELSKENVQ PLRQGRIMST LQGALAQESA CNNTLQQQKR
AFEYEIRFYT GNDPLDVWDR YISWTEQNYP QGGKESNMST LLERAVEALQ GEKRYYSDPR
FLNLWLKLGR LCNEPLDMYS YLHNQGIGVS LAQFYISWAE EYEARENFRK ADAIFQEGIQ
QKAEPLERLQ SQHRQFQARV SRQTLLALEK EEEEEVFESS VPQRSTLAEL KSKGKKTARA
PIIRVGGALK APSQNRGLQN PFPQQMQNNS RITVFDENAD EASTAELSKP TVQPWIAPPM
PRAKENELQA GPWNTGRSLE HRPRGNTASL IAVPAVLPSF TPYVEETARQ PVMTPCKIEP
SINHILSTRK PGKEEGDPLQ RVQSHQQASE EKKEKMMYCK EKIYAGVGEF SFEEIRAEVF
RKKLKEQREA ELLTSAEKRA EMQKQIEEME KKLKEIQTTQ QERTGDQQEE TMPTKETTKL
QIASESQKIP GMTLSSSVCQ VNCCARETSL AENIWQEQPH SKGPSVPFSI FDEFLLSEKK
NKSPPADPPR VLAQRRPLAV LKTSESITSN EDVSPDVCDE FTGIEPLSED AIITGFRNVT
ICPNPEDTCD FARAARFVST PFHEIMSLKD LPSDPERLLP EEDLDVKTSE DQQTACGTIY
SQTLSIKKLS PIIEDSREAT HSSGFSGSSA SVASTSSIKC LQIPEKLELT NETSENPTQS
PWCSQYRRQL LKSLPELSAS AELCIEDRPM PKLEIEKEIE LGNEDYCIKR EYLICEDYKL
FWVAPRNSAE LTVIKVSSQP VPWDFYINLK LKERLNEDFD HFCSCYQYQD GCIVWHQYIN
CFTLQDLLQH SEYITHEITV LIIYNLLTIV EMLHKAEIVH GDLSPRCLIL RNRIHDPYDC
NKNNQALKIV DFSYSVDLRV QLDVFTLSGF RTVQILEGQK ILANCSSPYQ VDLFGIADLA
HLLLFKEHLQ VFWDGSFWKL SQNISELKDG ELWNKFFVRI LNANDEATVS VLGELAAEMN
GVFDTTFQSH LNKALWKVGK LTSPGALLFQ
